Form 4: Suvretta Capital Management and Affiliates Report Beneficial Ownership Changes in Benitec Biopharma Inc.

Suvretta Capital Management, along with affiliated funds and individuals, filed a Form 4 disclosing changes in their beneficial ownership of Benitec Biopharma Inc. common stock and warrants due to warrant exercises.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd., and Aaron Cowen (collectively, the Reporting Persons) filed a Form 4 with the SEC.
• The filing reports transactions related to Benitec Biopharma Inc. (BNTC) common stock and warrants.
• The transactions occurred on September 26, 2024.
• The Reporting Persons exercised Series 2 warrants, common warrants, and pre-funded warrants to acquire shares of common stock.
• These warrants were issued on various dates, including September 15, 2022, and August 11, 2023.
• The exercises resulted in changes in the amount of common stock beneficially owned by the Reporting Persons.
• The Reporting Persons may be deemed to be a director by deputization due to Kishan Mehta serving on the board of directors of the Issuer.
• The board of directors of the Issuer approved the acquisition of any direct or indirect pecuniary interest in any and all shares by the Reporting Persons as a result of or in connection with the transactions reported in this Form 4.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership, which is common in the biotechnology industry where warrant exercises and equity transactions are frequent.

Key Dates